{"schema_version":"secwatch.filing_event.v1","accession":"0001860782-24-000007","form_type":"8-K","ticker":null,"cik":"0001860782","company_name":"2seventy bio, Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.122509+00:00","generated_at":"2026-06-06T15:15:22.028327+00:00","sec_items":["1.01","2.05","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"2seventy bio sells R&D to Regeneron ($5M), focuses on Abecma; cuts workforce ~14%","bullets":["Asset sale to Regeneron for $5M upfront, $10M milestone, royalties; ~160 employees transition; sublease facilities.","Workforce reduction of ~14%, remaining ~65 employees; one-time restructuring costs ~$8M.","Expected annual cost savings of ~$150M in 2024 and ~$200M in 2025; cash runway extended beyond 2027.","CEO Nick Leschly resigns upon closing, becomes Chair; COO Chip Baird named CEO; Victoria Eatwell named CFO.","Focus exclusively on Abecma with BMS; awaiting ODAC/PDUFA for potential third-line approval in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001860782-24-000007","json":"https://secwatch.observer/filing/0001860782-24-000007.json","markdown":"https://secwatch.observer/filing/0001860782-24-000007.md","text":"https://secwatch.observer/filing/0001860782-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/tvst-20240128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:15:22.028327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25216c27e3","claim":"Victoria Eatwell was appointed as Chief Financial Officer at 2seventy bio, Inc..","evidence_excerpt":"On January 29, 2024, the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"460b0f6806","claim":"Nick Leschly resigned as President and Chief Executive Officer at 2seventy bio, Inc..","evidence_excerpt":"On January 29, 2024, Nick Leschly informed the Company of his resignation as the Company’s president and chief executive officer effective upon the date of the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"94ad693ca3","claim":"William D. Baird, III was appointed as President and Chief Executive Officer at 2seventy bio, Inc..","evidence_excerpt":"On January 29, 2024, the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"98e12b3791818de4dd074493582a49432351195c","claim":"2seventy bio, Inc. entered into Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at $5 million in cash (effective 2024-01-29).","evidence_excerpt":"On January 29, 2024, 2seventy bio, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Regeneron Pharmaceuticals, Inc."},{"label":"Value","value":"$5 million in cash"},{"label":"Effective","value":"2024-01-29"}],"fact_type":"material_agreement"},{"claim_id":"388a08ff1ad1e1651db9e7d45cfcd092a6e2d493","claim":"2seventy bio, Inc. announced a restructuring with charges of approximately $8 million affecting the entire company (approximately 14%).","evidence_excerpt":"complete by the end of the second quarter of 2024. In connection with the workforce reduction and restructuring, the Company expects to incur one-time costs of approximately $8 million, primarily in the first half of 2024, relating to severance and retention packages and related benefits. The estimates of expenses and cash costs that the Company expects to","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $8 million"},{"label":"Affected area","value":"the entire company"},{"label":"Headcount","value":"approximately 14%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}